Literature DB >> 9920814

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

H Satoh1, K Tsukamoto, Y Hashimoto, N Hashimoto, M Togo, M Hara, H Maekawa, N Isoo, S Kimura, T Watanabe.   

Abstract

We examined the effect of troglitazone on immunoreactive endothelin-1 (ET-1) secretion from cultured bovine vascular endothelial cells (bVECs). Insulin (10(-9)-10(-7) M) stimulated ET-1 secretion in a dose-dependent fashion without any kinetic change. Troglitazone (1-20 microM) dose-dependently inhibited both spontaneous and insulin-stimulated ET-1 secretion. This inhibitory effect of troglitazone was associated with reduced ET-1 mRNA levels. Addition of indomethacin (100 microM) or Nw-nitro-l-arginine methyl ester (1 mM) and downregulation of protein kinase C by prolonged pretreatment of the cells with a phorbol ester, 12-O-tetradecanoylphorbol 13-acetate, did not affect the inhibitory effect of troglitazone at concentrations up to 10 microM. Troglitazone did not change the intracellular Ca2+ concentration stimulated by angiotensin II (10 microM). Other PPARgamma ligands, pioglitazone (1-10 microM) and 15-deoxy-delta 12, 14-prostaglandin J2 (1-10 microM), but not a PPARalpha ligand, bezafibrate (1-10 microM), dose-dependently suppressed spontaneous ET-1 secretion from bVECs. These results, taken together, suggest that troglitazone inhibits ET-1 mRNA expression and secretion in bVECs possibly through activation of PPARgamma. This inhibition may contribute to the hypotensive effect of troglitazone in insulin-resistant subjects. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920814     DOI: 10.1006/bbrc.1998.0126

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 2.  Pathogenesis of hypertension in diabetes.

Authors:  Sameer N Stas; Fadi A El-Atat; James R Sowers
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 3.  PPAR-γ -- a possible drug target for complicated pregnancies.

Authors:  Fergus P McCarthy; Aoife C Delany; Louise C Kenny; Sarah K Walsh
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 4.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

5.  Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells.

Authors:  Philip Funovics; Christine Brostjan; Anneliese Nigisch; Anna Fila; Anna Grochot; Katarzyna Mleczko; Halina Was; Guenter Weigel; Jozef Dulak; Alicja Jozkowicz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-03-31       Impact factor: 3.072

6.  Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

Authors:  Ningning Wang; J David Symons; Hui Zhang; Zhanjun Jia; Frank J Gonzalez; Tianxin Yang
Journal:  Toxicol Pathol       Date:  2008-12-15       Impact factor: 1.902

7.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

8.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

9.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

10.  Significant synergistic effect of peroxisome proliferator-activated receptor gamma C-2821T and diabetes on the risk of ischemic stroke.

Authors:  Fang-I Hsieh; Wei-Cheng Lo; Huey-Juan Lin; Yi-Chen Hsieh; Li-Ming Lien; Chyi-Huey Bai; Hung-Pin Tseng; Hung-Yi Chiou
Journal:  Diabetes Care       Date:  2009-08-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.